Omega-3 polyunsaturated fatty acid supplementation improves lipid metabolism and endothelial function by providing a beneficial eicosanoid-pattern in patients with acute myocardial infarction: A randomized, controlled trial

Autor: Xu Zhang, Xiang-Li Liu, Yi Zhu, Yue Zhang, Tong Liu, Guangping Li, Meng Yuan, Ruyu Yuan, Tong Hua
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Myocardial Infarction
030209 endocrinology & metabolism
Pharmacology
Nitric Oxide
Critical Care and Intensive Care Medicine
Leukotriene B4
Nutrition Policy
law.invention
03 medical and health sciences
chemistry.chemical_compound
Percutaneous Coronary Intervention
0302 clinical medicine
Randomized controlled trial
law
Atrial Fibrillation
Fatty Acids
Omega-3
medicine
Humans
Metabolomics
Myocardial infarction
Aged
chemistry.chemical_classification
030109 nutrition & dietetics
Nutrition and Dietetics
Prostaglandin D2
business.industry
Lipid metabolism
Middle Aged
Lipid Metabolism
medicine.disease
Eicosapentaenoic acid
Intention to Treat Analysis
Death
Sudden
Cardiac
chemistry
Eicosanoid
Docosahexaenoic acid
Acute Disease
Dietary Supplements
Metabolome
Eicosanoids
Female
lipids (amino acids
peptides
and proteins)
Arachidonic acid
Endothelium
Vascular
business
Polyunsaturated fatty acid
Zdroj: Clinical Nutrition. 40:445-459
ISSN: 0261-5614
DOI: 10.1016/j.clnu.2020.05.034
Popis: Omega-3 polyunsaturated fatty acid (ω-3 PUFA) have been reported to have beneficial cardiovascular effects, but its mechanism of protection against acute myocardial infarction (AMI) who are under guideline-based therapy is not fully understood. Here, we used a metabolomic approach to systematically analyze the eicosanoid metabolites induced by ω-3 PUFA supplementation and investigated the underlying mechanisms.Participants with AMI after successful percutaneous coronary intervention were randomized to 3 months of 2 g daily ω-3 PUFA and guideline-adjusted therapy (n = 30, ω-3 therapy) or guideline-adjusted therapy alone (n = 30, Usual therapy). Functional PUFA-derived eicosanoids in plasma were profiled by metabolomics. Clinical and laboratory tests were obtained before and 3 months after baseline and after the study therapy.By intent-to-treat analysis, the content of 11-HDoHE, 20-HDoHE and 16,17-EDP and that of epoxyeicosatetraenoic acids (EEQs), derived from docosahexaenoic acid and eicosapentaenoic acid, respectively, were significantly higher with ω-3 group than Usual therapy, whereas that of prostaglandin J2 (PGJ2) and leukotriene B4, derived from arachidonic acid, was significantly decreased. As compared with Usual therapy, ω-3 PUFA therapy significantly reduced levels of triglycerides (-6.3%, P 0.05), apolipoprotein B (-4.9%, P 0.05) and lipoprotein(a) (-37.0%, P 0.05) and increased nitric oxide level (62.2%, P 0.05). In addition, the levels of these variables were positively correlated with change in 16,17-EDP and EEQs content but negatively with change in PGJ2 content.ω-3 PUFA supplementation may improve lipid metabolism and endothelial function possibly by affecting eicosanoid metabolic status at a systemic level during convalescent healing after AMI.URL: http://www.chictr.org.cn. Unique identifier: ChiCTR1900025859.
Databáze: OpenAIRE
Externí odkaz: